- Home
- BBOT vs TNDM Comparison
BBOT vs TNDM Comparison
Compare BBOT & TNDM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BBOT | TNDM |
|---|---|---|
| Founded | 2016 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.1B |
| IPO Year | N/A | 2013 |
Fundamental Metrics
Financial Performance| Metric | BBOT | TNDM |
|---|---|---|
| Price | $13.69 | $20.92 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 16 |
| Target Price | ★ $23.80 | $22.00 |
| AVG Volume (30 Days) | 168.9K | ★ 2.7M |
| Earning Date | 11-12-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $1,007,001,000.00 |
| Revenue This Year | N/A | $8.59 |
| Revenue Next Year | N/A | $10.19 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 17.87 |
| 52 Week Low | $8.50 | $9.98 |
| 52 Week High | $14.78 | $38.28 |
Technical Indicators
Market Signals| Indicator | BBOT | TNDM |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 64.34 |
| Support Level | N/A | $19.47 |
| Resistance Level | N/A | $21.07 |
| Average True Range (ATR) | 0.00 | 1.15 |
| MACD | 0.00 | -0.08 |
| Stochastic Oscillator | 0.00 | 69.86 |
Price Performance
Historical ComparisonAbout BBOT BridgeBio Oncology Therapeutics Inc. Common Stock
BridgeBio Oncology Therapeutics Inc, formerly BridgeBio Oncology Therapeutics is a clinical-stage biotechnology company that aims to transform the lives of patients with cancers driven by RAS and PI3Ka, the two frequently mutated oncogenes.
About TNDM Tandem Diabetes Care Inc.
Tandem Diabetes designs, manufactures, and markets durable insulin pumps for diabetes patients. The firm first entered this market in 2012 and has since introduced multiple generations of pumps leading to its current t:slim X2 device. The firm recently launched its smaller Mobi pump and continues to work on a tubeless patch pump. Nearly three-quarters of total revenue is derived from the US, with the remainder primarily from other developed nations. The pumps themselves generate just over half of total sales, and another one third is from disposable infusion sets that need to be changed over every 2 to 3 days.